Y Intercept Hong Kong Ltd boosted its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 193.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 19,151 shares of the biopharmaceutical company's stock after purchasing an additional 12,617 shares during the period. Y Intercept Hong Kong Ltd's holdings in Ultragenyx Pharmaceutical were worth $1,064,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Millennium Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 103.8% in the second quarter. Millennium Management LLC now owns 1,850,734 shares of the biopharmaceutical company's stock valued at $76,065,000 after purchasing an additional 942,529 shares during the period. Alkeon Capital Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 34.3% in the third quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company's stock worth $167,301,000 after acquiring an additional 769,884 shares in the last quarter. Two Sigma Advisers LP increased its position in shares of Ultragenyx Pharmaceutical by 123.4% during the third quarter. Two Sigma Advisers LP now owns 987,800 shares of the biopharmaceutical company's stock worth $54,872,000 after acquiring an additional 545,600 shares during the period. Frazier Life Sciences Management L.P. acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at $17,468,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Ultragenyx Pharmaceutical by 63.8% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 830,375 shares of the biopharmaceutical company's stock valued at $34,128,000 after purchasing an additional 323,280 shares during the period. Hedge funds and other institutional investors own 97.67% of the company's stock.
Insider Activity
In other news, CFO Howard Horn sold 7,465 shares of the firm's stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the sale, the chief financial officer now owns 92,301 shares in the company, valued at approximately $4,869,800.76. This trade represents a 7.48 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Emil D. Kakkis sold 8,273 shares of Ultragenyx Pharmaceutical stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total transaction of $413,650.00. Following the completion of the sale, the chief executive officer now directly owns 2,195,712 shares in the company, valued at approximately $109,785,600. The trade was a 0.38 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.80% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on RARE shares. Canaccord Genuity Group restated a "buy" rating and set a $121.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, November 12th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $116.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. TD Cowen boosted their price target on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Royal Bank of Canada restated an "outperform" rating and issued a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Finally, HC Wainwright boosted their target price on shares of Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the stock a "buy" rating in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $87.46.
Get Our Latest Stock Report on Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Trading Down 2.4 %
RARE traded down $1.11 during trading on Friday, hitting $45.78. 794,195 shares of the stock were exchanged, compared to its average volume of 772,828. Ultragenyx Pharmaceutical Inc. has a 1-year low of $37.02 and a 1-year high of $60.37. The stock has a fifty day moving average price of $50.63 and a two-hundred day moving average price of $49.05.
Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.05. The firm had revenue of $139.49 million during the quarter, compared to the consensus estimate of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. Ultragenyx Pharmaceutical's revenue for the quarter was up 42.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.23) EPS. On average, research analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.2 EPS for the current year.
Ultragenyx Pharmaceutical Profile
(
Free Report)
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Read More
Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.
While Ultragenyx Pharmaceutical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.